Loading...
XKRX
000020
Market cap116mUSD
Dec 05, Last price  
6,210.00KRW
1D
-0.16%
1Q
-2.51%
Jan 2017
-23.52%
Name

Dongwha Pharm Co Ltd

Chart & Performance

D1W1MN
XKRX:000020 chart
P/E
30.94
P/S
0.37
EPS
200.71
Div Yield, %
—
Shrs. gr., 5y
0.08%
Rev. gr., 5y
8.64%
Revenues
464.87b
+28.74%
148,738,623,000175,119,773,000188,607,515,000145,115,173,000215,279,424,000234,561,984,470223,371,996,540220,240,574,700213,472,144,940223,201,285,430237,470,834,800258,881,616,580306,602,589,030307,150,025,790272,075,383,800293,018,112,030340,426,327,300361,108,562,000464,874,735,000
Net income
5.56b
-79.72%
8,065,194,00021,495,381,00028,518,530,0006,717,401,0005,427,207,00017,679,223,0701,311,240,9201,011,859,7504,937,204,9605,608,652,16026,254,318,41047,009,013,18010,068,506,3809,402,231,12028,507,687,36017,870,404,58020,383,458,97027,438,289,7615,563,245,000
CFO
-4.00b
L
23,185,889,00023,655,312,00031,155,090,00029,920,326,00018,587,828,00046,244,031,85025,226,760,3608,205,110,34013,514,667,97019,833,109,34025,482,187,950-16,519,974,690-4,360,077,74013,284,966,21052,228,225,09036,031,211,87029,220,766,68029,166,607,898-4,003,244,000
Dividend
Dec 27, 2023180 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Dongwha Pharm Co., Ltd. manufactures and sells pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/respiratory system, muscle relaxant/musculoskeletal system, nervous system, and dermatological/urinary system; OTC products in the areas of alimentary system, cold remedy, NSAID/respiratory system, dermatological, mouth and teeth, hepatic protector, nutrient, tonic, topic analgesic, antihistamines, sore throat, and others; quasi drugs; health subsidiary foods; foods and drinks; and cosmetics. The company was founded in 1897 and is based in Seoul, South Korea.
URL
http://www.dong-wha.co.kr/
IPO date
Mar 24, 1976
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT